2026/0123 - Direct Award for the Acquisition of TEPOTINIB [225 MG; CAP/COMP]
About This Opportunity
TranslatedThis tender, referenced as 2026/0123, is a direct award procedure for the procurement of the pharmaceutical drug Tepotinib. The specific dosage and formulation requested are 225 mg, in capsule or tablet form (CÁP/COMP). A direct award ('Ajuste direto') indicates that the contracting authority has selected a specific supplier without a full open tendering process, likely due to specific justifications such as a sole supplier, an urgent need, or a prior framework agreement. Tepotinib is a targeted therapy drug used in the treatment of certain types of cancer, specifically non-small cell lung cancer (NSCLC) with specific genetic mutations (MET exon 14 skipping). The procurement is focused on acquiring this specific medication, which is critical for patient treatment. The tender documents, even in a direct award context, would typically outline the justification for the direct award, the quantity of the drug required, the supplier's details, and the contract value. The objective is to ensure that patients have access to this essential medication in a timely manner. The process emphasizes the need for a reliable supply of high-quality, approved pharmaceutical products for medical use.
This is a supplies contract in the health and medical services, trade and industry and general supplies sectors, with a focus on Pharmaceuticals and Manufacturing. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 34,136.
Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.
Description
Original language: PortugueseThis tender, identified as 2026/0123, is an urgent direct award procurement seeking the acquisition of Tepotinib, specifically in its 225 mg dosage form, available as capsules or tablets. The contracting authority is based in Portugal, as indicated by the source database, Portal BASE, which centralizes public contract information for both mainland Portugal and its autonomous regions.
This procurement falls under the pharmaceutical and medical supplies category, addressing a critical need for a specific medication. Direct award tenders are typically utilized when there is an urgent requirement, a single supplier is capable of meeting the demand, or for specific reasons of public interest that preclude a competitive bidding process. While specific technical specifications for the Tepotinib will be detailed in the full tender documentation, typical requirements for such pharmaceutical acquisitions would include adherence to stringent quality standards, such as Good Manufacturing Practices (GMP), and compliance with relevant national and European Union pharmaceutical regulations.
Bidders are expected to provide evidence of their ability to supply the specified medication, including details on product registration, batch traceability, and appropriate packaging and labeling for the Portuguese market. Furthermore, the tender will likely outline requirements related to delivery timelines, storage conditions, and after-sales support, ensuring the integrity and efficacy of the product from procurement to patient administration. Interested parties should consult the full tender documents for precise eligibility criteria and submission instructions.
Data provenance
This notice is sourced from base_gov_pt and was originally published on March 9, 2026. Last refreshed 5 days ago. Original language: Portuguese. BidsFactory mirrors official procurement notices and links back to the source for full legal text.
About IPO Porto FG, EPE
IPO Porto FG, EPE has issued 515 procurement notices on BidsFactory, including 0 currently open and 504 awarded contracts. Activity concentrates in General Supplies & Services, Health & Medical, and Information & Communication Technology. All notices are published for Portugal. Notices are distributed via base_gov_pt. Most recent publication: June 15, 2026.
Frequently asked questions about this tender
What type of contract is this?
This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.
What is the estimated budget?
The estimated contract value is Up to €34,136. Bidders should ensure their proposals are consistent with this range and account for any local taxes and contract execution costs.
Where will the contract be performed?
The contract is for delivery in Portugal. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.
How can I submit a bid?
Visit base_gov_pt to access the full notice, required documents, and submission instructions provided by the contracting authority.
Is this tender still open?
No — the contract has already been awarded to MERCK, SA. The award notice is archived on BidsFactory for transparency and market intelligence.
Who is the contracting authority?
This notice was issued by IPO Porto FG, EPE in Portugal. The authority is responsible for evaluating bids, awarding the contract, and managing performance.
Find tenders like this automatically
Set up alerts and filters that match your business — never miss a relevant opportunity again.